Merck analysts to CEO: What’s so great about your pipeline beyond Keytruda?

Merck's reliance on its blockbuster I-O drug Keytruda has worried market watchers for awhile, and now that 2019 revenue expectations are on the low side, those worries have intensified. Yes, Keytruda soared 66% in the fourth quarter, but the company badly needs to diversify beyond the star drug, analysts said.